Stock screener

RGNX

Conviction 58HealthcareScan · Thu, Jun 25, 2026
Shooting star
RGNX$10.21+2.41%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 2.59M
Mar 26Apr 14May 1May 19Jun 8Jun 25
REGENXBIO Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.regenxbio.com
Price10.21
Change+2.41%
Gap+1.00%
Rel volume1.42×
Avg volume2.21M
Avg $ vol17.65M
SMA 207.38
SMA 508.01
SMA 20010.34
Price vs 50+27.41%
Price vs 200-1.28%
MA stackmixed
50/200 cross
Supertrendup · 7.81
RSI (14)72
MACD hist0.49
MACD cross
Stoch %K / %D85 / 85
ADX (14)24
+DI / −DI40 / 12
RSI divergence
MACD divergence
ATR %+8.03%
ADR %9.00%
52w high15.98
52w low5.65
From 52w high-36.11%
Above 52w low+80.71%
New 52w highNo
SqueezeOff
Bollinger width71.11%
%B1.04
Donchian pos84.90%
Donchian high10.98
Donchian low5.88
AVWAP (52w high)8.46
vs AVWAP high+20.73%
AVWAP (52w low)7.53
vs AVWAP low+35.50%
OBV trendUp
Chaikin MF (20)0.01
Today vs 20d1.42×
Avg vol (14d)2.59M
Avg vol (20d)2.21M
Avg $ vol (20d)17.65M
Market cap527.83M
RS 3m (vs SPY)+15.40%
RS 6m (vs SPY)-39.40%
RS line new highNo
Trend template3/8
Technical rank53.0
1 week+29.24%
1 month+61.81%
3 months+20.69%
6 months-31.80%
1 year+19.28%
YTD-24.76%
P/E-2.72
P/B25.04
P/S3.10
P/FCF-4.18
EPS-3.76
Div yield
ROE-919.64%
ROA-56.71%
Debt/Eq
Current2.62
EV/EBITDA-3.52
Gross margin
Net margin-113.75%
Rev growth104.54%
EPS growth14.63%
Price target20.89
Target upside104.60%
Analyst ratingBuy
Institutional89.53%
Ent. value512.6M
Revenue6.39M
Net income-90.05M
Gross profit
Free cash flow-126.38M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out51.7M
Employees371
ListedThu, Sep 17, 2015
Free float38.66M
Float %74.9%
Short interest8.28M
Days to cover4.5d
Short volume43.3%
Squeeze score71 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast$0.12 · 5 est
Last EPS vs est−$1.72 vs −$1.36
Last surprise-26.5% miss
Setup gradeC
Conviction58 / 100
Pattern quality
Tech rank53.0 / 100
Group rank50 / 100
Status lane
Setup direction
Pattern family
Resistance
Support
Days since event
Candle confirmShooting star
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RGNX

All disclosures →
No recent disclosed trades by Congress in RGNX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RGNX · 10 buys

InsiderSideShares
Bennett Jean
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Tasse Daniel
Director · Common Stock · 2026-05-29
Grant9.81K
Zachary Jennifer
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Glucksmann Alexandra
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
KARABELAS ARGERIS N
Director · Common Stock · 2026-05-29
Grant9.81K
Glucksmann Alexandra
Director · Common Stock · 2026-05-29
Grant9.81K
Tasse Daniel
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Zachary Jennifer
Director · Common Stock · 2026-05-29
Grant9.81K
Fox Allan M.
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
KARABELAS ARGERIS N
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K

SEC filings

EDGAR filings in RGNX · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.